ATE230989T1 - Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems - Google Patents
Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystemsInfo
- Publication number
- ATE230989T1 ATE230989T1 AT93920438T AT93920438T ATE230989T1 AT E230989 T1 ATE230989 T1 AT E230989T1 AT 93920438 T AT93920438 T AT 93920438T AT 93920438 T AT93920438 T AT 93920438T AT E230989 T1 ATE230989 T1 AT E230989T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- sec
- anabasein
- derivatives
- treatment
- Prior art date
Links
- 230000003412 degenerative effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000000653 nervous system Anatomy 0.000 title 1
- AUBPMADJYNSPOA-UHFFFAOYSA-N Anabaseine Chemical compound C1CCCC(C=2C=NC=CC=2)=N1 AUBPMADJYNSPOA-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 3-substituted 2,4-dimethoxy-benzylidene Chemical group 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000001054 cortical effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93842792A | 1992-08-31 | 1992-08-31 | |
| PCT/US1993/008192 WO1994005288A1 (en) | 1992-08-31 | 1993-08-31 | Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE230989T1 true ATE230989T1 (de) | 2003-02-15 |
Family
ID=25471422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93920438T ATE230989T1 (de) | 1992-08-31 | 1993-08-31 | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5741802A (de) |
| EP (1) | EP0659078B1 (de) |
| JP (1) | JP3034953B2 (de) |
| KR (1) | KR100272614B1 (de) |
| AT (1) | ATE230989T1 (de) |
| AU (1) | AU674541B2 (de) |
| CA (1) | CA2142610C (de) |
| DE (1) | DE69332641T2 (de) |
| WO (1) | WO1994005288A1 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0659078B1 (de) * | 1992-08-31 | 2003-01-15 | University Of Florida Research Foundation, Inc. | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems |
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
| US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
| DE69825605T2 (de) | 1997-05-29 | 2005-09-15 | H. Lundbeck A/S | Behandlung der schizophrenie und der psychose |
| US6708055B2 (en) * | 1998-08-25 | 2004-03-16 | University Of Florida | Method for automated analysis of apical four-chamber images of the heart |
| US6346124B1 (en) | 1998-08-25 | 2002-02-12 | University Of Florida | Autonomous boundary detection system for echocardiographic images |
| US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US6448276B1 (en) | 2000-05-17 | 2002-09-10 | Inspire Pharmaceuticals, Inc. | Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| WO2003072135A2 (en) * | 2002-02-26 | 2003-09-04 | North Shore-Long Island Jewish Research Insitute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| US7244745B2 (en) * | 2002-08-30 | 2007-07-17 | Memory Pharmaceuticals Corp. | Heterocyclic compounds, methods for the preparation thereof, and uses thereof |
| CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| ATE378048T1 (de) * | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| RU2259364C1 (ru) * | 2004-04-01 | 2005-08-27 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, включающие фрагмент пиперидин-2-ила-, фокусированные библиотеки и фармацевтические композиции |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| WO2005092890A2 (en) | 2004-03-25 | 2005-10-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| CA2560756A1 (en) * | 2004-03-25 | 2005-10-06 | The Feinstein Institute For Medical Research | Methods and devices for reducing bleed time using vagus nerve stimulation |
| US20050288333A1 (en) * | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| EP2298410B1 (de) | 2004-12-27 | 2013-10-09 | The Feinstein Institute for Medical Research | Behandlung von entzündlichen Erkrankungen durch elektrische Stimulation des Vagusnervs |
| EP1891036A4 (de) | 2005-06-07 | 2010-08-04 | Univ Florida | Selektive liganden für alpha-7-nikotinrezeptoren |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| US7662965B2 (en) * | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| EP2271344A4 (de) * | 2008-03-31 | 2011-04-27 | Univ South Florida | Verfahren zur behandlung von krankheitsinduzierter ataxie und nicht-ataxischem ungleichgewicht |
| WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
| JP2011520964A (ja) * | 2008-05-23 | 2011-07-21 | ユニバーシティ・オブ・サウス・フロリダ | ニコチン性アセチルコリン受容体活性を有する化合物を用いる末梢感覚神経喪失の治療方法 |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| MX2012002209A (es) * | 2009-08-21 | 2012-07-25 | Univ Florida | Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos. |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| EP2515996B1 (de) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Nervenstimulatoren und systeme zur behandlung von chronischer entzündung |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| MX2013000391A (es) * | 2010-07-12 | 2013-03-08 | Hoffmann La Roche | 1-hidroxiimino-3-fenil-propanos. |
| WO2012031220A2 (en) | 2010-09-03 | 2012-03-08 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| EP2707094B1 (de) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Einzelimpulsaktivierung des cholinergen entzündungshemmenden pfades zur behandlung chronischer entzündungen |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| EP3405255B1 (de) | 2016-01-20 | 2025-12-31 | Setpoint Medical Corporation | Implantierbare mikrostimulatoren und induktive ladesysteme |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US11096932B2 (en) | 2016-09-29 | 2021-08-24 | The Uab Research Foundation | Methods and compositions for increasing mucus clearance |
| US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| WO2020210786A1 (en) | 2019-04-12 | 2020-10-15 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| JP2023512447A (ja) | 2020-01-13 | 2023-03-27 | ザ ファインスタイン インスティチューツ フォー メディカル リサーチ | 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療 |
| KR20230012585A (ko) | 2020-05-21 | 2023-01-26 | 더 파인스타인 인스티튜츠 포 메디칼 리서치 | 미주 신경 자극을 위한 시스템들 및 방법들 |
| GB2612481A (en) * | 2020-06-09 | 2023-05-03 | Fadly Abd El Ghany Elkazaz Mohamed | A novel medicament for immune modulation and treating chronic or hyper inflammation |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| US20250229086A1 (en) | 2022-01-20 | 2025-07-17 | Setpoint Medical Corporation | Treatment of inflammatory disorders |
| US12649059B2 (en) | 2022-08-05 | 2026-06-09 | The Feinstein Institutes For Medical Research | Methods for reducing bleeding in hemophilia by vagus nerve stimulation to prime platelets |
| CN118851892B (zh) * | 2023-04-20 | 2026-07-21 | 成都新睿泰康科技有限公司 | 一种1-(环丁亚基甲基)-2,4,5-三甲氧基苯化合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3275625A (en) * | 1966-09-27 | Derivatives of | ||
| US3426130A (en) * | 1960-12-19 | 1969-02-04 | Squibb & Sons Inc | Compositions containing a benzothiadiazinesulfonamide 1,1-dioxide |
| US3247213A (en) * | 1961-04-12 | 1966-04-19 | Shell Oil Co | Heterocyclic nitrogen compounds |
| US3265573A (en) * | 1962-07-27 | 1966-08-09 | Squibb & Sons Inc | Benzothiadiazinesulfonamide-1, 1-dioxide composition |
| US4155909A (en) * | 1977-06-13 | 1979-05-22 | Philip Morris Incorporated | 2-Alkyl nicotinoids and processes for their production |
| US4195645A (en) * | 1978-03-13 | 1980-04-01 | Celanese Corporation | Tobacco-substitute smoking material |
| US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
| AU652434B2 (en) * | 1991-03-01 | 1994-08-25 | University Of Florida Research Foundation, Inc. | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| EP0659078B1 (de) * | 1992-08-31 | 2003-01-15 | University Of Florida Research Foundation, Inc. | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems |
| US5488049A (en) * | 1993-12-10 | 1996-01-30 | Fidia - Georgetown Institute For The Neuro-Sciences | Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents |
-
1993
- 1993-08-31 EP EP93920438A patent/EP0659078B1/de not_active Expired - Lifetime
- 1993-08-31 DE DE69332641T patent/DE69332641T2/de not_active Expired - Lifetime
- 1993-08-31 AT AT93920438T patent/ATE230989T1/de not_active IP Right Cessation
- 1993-08-31 JP JP06507391A patent/JP3034953B2/ja not_active Expired - Fee Related
- 1993-08-31 AU AU50979/93A patent/AU674541B2/en not_active Ceased
- 1993-08-31 WO PCT/US1993/008192 patent/WO1994005288A1/en not_active Ceased
- 1993-08-31 CA CA002142610A patent/CA2142610C/en not_active Expired - Lifetime
- 1993-08-31 KR KR1019950700698A patent/KR100272614B1/ko not_active Expired - Fee Related
- 1993-08-31 US US08/392,763 patent/US5741802A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0659078A4 (de) | 1996-04-24 |
| US5741802A (en) | 1998-04-21 |
| KR100272614B1 (ko) | 2000-11-15 |
| EP0659078B1 (de) | 2003-01-15 |
| CA2142610C (en) | 2003-09-16 |
| JP3034953B2 (ja) | 2000-04-17 |
| AU5097993A (en) | 1994-03-29 |
| WO1994005288A1 (en) | 1994-03-17 |
| CA2142610A1 (en) | 1994-03-17 |
| DE69332641T2 (de) | 2003-11-27 |
| AU674541B2 (en) | 1997-01-02 |
| KR950702829A (ko) | 1995-08-23 |
| EP0659078A1 (de) | 1995-06-28 |
| JPH08509458A (ja) | 1996-10-08 |
| DE69332641D1 (de) | 2003-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69332641D1 (de) | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems | |
| BR9709501A (pt) | Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto | |
| LTIP919A (en) | Drugs and process for preparing thereof | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE198830T1 (de) | Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems | |
| ATE302194T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
| ATE168007T1 (de) | Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| HUP0001062A2 (hu) | NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények | |
| ATE188377T1 (de) | Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose | |
| HUT73433A (en) | Process for preparing pharmaceutical compositions containing riluzole for treating aids-related neural disorders | |
| PL313716A1 (en) | Tetrachloropyridino-(or 4-hydroxypiperidino) alkyloazoles exhibiting activity in respect to sigma and/or 5ht1a receptor | |
| ATE455773T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| TR199700711T1 (xx) | Ciltten ge�erek v�cuda giren form�lasyon. | |
| ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| ATE222491T1 (de) | Melatonin-derivate zur verwendung in der behandlung von schlafstörungen | |
| DE69432626D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen | |
| ATE216891T1 (de) | Verwendung von immunosuppressiva zur behandlung der schizophrenie | |
| DE69701258D1 (de) | Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems | |
| IL117083A0 (en) | Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical agents containing these compounds | |
| NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
| GR3034661T3 (en) | Use of Selegiline in vetenary medicine. | |
| ATE283269T1 (de) | 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems | |
| DE59409813D1 (de) | Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen | |
| DE69413554D1 (de) | IMIDAZO [1,5-a] CHINOLINE ZUR BEHANDLUNG VON ANGSTZUSTÄNDEN UND SCHLAFSTÖRUNGEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |